Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
$0.0001 +0.00 (+∞)
As of 12:13 PM Eastern
Compare

CMRA vs. SYRS, TRVN, NAVB, GNCA, and PXMD

Should you buy Comera Life Sciences stock or one of its competitors? Comera Life Sciences's main competitors and comparable companies include Syros Pharmaceuticals (SYRS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), and PaxMedica (PXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Comera Life Sciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Comera Life Sciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Comera Life Sciences N/A N/A N/A

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Comera Life Sciences Neutral

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Comera Life Sciences has higher revenue and earnings than Syros Pharmaceuticals. Comera Life Sciences is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Summary

Syros Pharmaceuticals and Comera Life Sciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Comera Life Sciences compare to Trevena?

Trevena (NASDAQ:TRVN) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Trevena has a beta of -0.55, indicating that its share price is 155% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Comera Life Sciences has higher revenue and earnings than Trevena. Comera Life Sciences is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Comera Life Sciences N/A N/A N/A

In the previous week, Trevena had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Comera Life Sciences. Trevena's average media sentiment score of 0.37 beat Comera Life Sciences' score of 0.00 indicating that Trevena is being referred to more favorably in the media.

Company Overall Sentiment
Trevena Neutral
Comera Life Sciences Neutral

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Comera Life Sciences beats Trevena on 6 of the 11 factors compared between the two stocks.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Comera Life Sciences. Comera Life Sciences is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Navidea Biopharmaceuticals Neutral

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Comera Life Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Comera Life Sciences has lower revenue, but higher earnings than Genocea Biosciences. Comera Life Sciences is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Comera Life Sciences Neutral

Comera Life Sciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Comera Life Sciences N/A N/A N/A

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Comera Life Sciences beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to PaxMedica?

Comera Life Sciences (NASDAQ:CMRA) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

4.9% of PaxMedica shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Comera Life Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

Comera Life Sciences has higher revenue and earnings than PaxMedica. Comera Life Sciences is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
PaxMedica Neutral

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / Sales0.00850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net Income-$18M$2.83B$3.49B$360.00M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/A$0.00
+∞		N/AN/A$3K$1.00MN/A2
SYRS
Syros Pharmaceuticals
N/A$0.00
-96.7%		N/A+300.0%$11K$386KN/A120
TRVN
Trevena
N/A$0.01
flat		N/A+12.0%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel